CD8A and chronic inflammatory demyelinating polyradiculoneuropathy: The broad efficacy of IVIg in the treatment of CIDP is rooted in the ability to exert a number of different mechanisms of action [4] such as the reduction in oligoclonal T cell expansion, particularly within the CD8+ T cell population [20].